Form 4: Contineum Therapeutics Director Todd R. Brady Granted Stock Options

Director Todd R. Brady receives 29,500 stock options in Contineum Therapeutics under the company's 2024 Equity Incentive Plan.

Summary

• Todd R. Brady, a director of Contineum Therapeutics, was granted 29,500 stock options on May 24, 2024.
• The options were granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended.
• The exercise price of the options is $15.76.
• One-third of the option shares vest on April 5, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to continuous service.
• The options expire on May 23, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• The vesting schedule of one-third on the first anniversary and the remainder over 24 months is a typical vesting arrangement.
• Comparable companies such as BioNTech, Moderna, and Novavax also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the option grant positively as it incentivizes the director to increase shareholder value.

Key Dates